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Abstract
Guanidino compounds (GCs), such as creatine, phosphocreatine, guanidinoacetic acid, creatinine, methylguanidine,
guanidinosuccinic acid, g-guanidinobutyric acid, b-guanidinopropionic acid, guanidinoethane sulfonic acid and a-
guanidinoglutaric acid, are present in the mammalian brain. Although creatine and phosphocreatine play
important roles in energy homeostasis in the brain, accumulation of GCs may induce epileptic discharges and
convulsions. This review focuses on how physiologically important and/or neurotoxic GCs are distributed in the
brain under physiological and pathological conditions. Transporters for GCs at the blood-brain barrier (BBB) and the
blood-cerebrospinal fluid (CSF) barrier (BCSFB) have emerged as substantial contributors to GCs distribution in the
brain. Creatine transporter (CRT/solute carrier (SLC) 6A8) expressed at the BBB regulates creatine concentration in
the brain, and represents a major pathway for supply of creatine from the circulating blood to the brain. CRT may
be a key factor facilitating blood-to-brain guanidinoacetate transport in patients deficient in S-adenosylmethionine:
guanidinoacetate N-methyltransferase, the creatine biosynthetic enzyme, resulting in cerebral accumulation of
guanidinoacetate. CRT, taurine transporter (TauT/SLC6A6) and organic cation transporter (OCT3/SLC22A3) expressed
at the BCSFB are involved in guanidinoacetic acid or creatinine efflux transport from CSF. Interestingly, BBB efflux
transport of GCs, including guanidinoacetate and creatinine, is negligible, though the BBB has a variety of efflux
transport systems for synthetic precursors of GCs, such as amino acids and neurotransmitters. Instead, the BCSFB
functions as a major cerebral clearance system for GCs. In conclusion, transport of GCs at the BBB and BCSFB
appears to be the key determinant of the cerebral levels of GCs, and changes in the transport characteristics may
cause the abnormal distribution of GCs in the brain seen in patients with certain neurological disorders.
Introduction
Guanidino compounds (GCs), such as creatine (CT),
phosphocreatine (PCT), guanidinoacetic acid (GAA),
creatinine (CTN), methylguanidine (MG), guanidinosuc-
cinic acid (GSA), g-guanidinobutyric acid (GBA), b-gua-
nidinopropionic acid (GPA), guanidinoethane sulfonic
acid (GES) and a-guanidinoglutaric acid (GGA), are pre-
sent in the mammalian brain at individual concentra-
tions in the nanomolar to millimolar range [1-3]. CT
and PCT play a pivotal role in the storage and utiliza-
tion of phosphate-bound ene r g yv i aC Tk i n a s ei nt h e
brain, thus serving to maintain energy homeostasis in
the brain [4]. In this CT/PCT/CT kinase shuttle system,
the phosphate-bound energy of ATP is transferred to
CT and stored as PCT to be used for regenerating ATP
from ADP [4]. On the other hand, GCs are known to be
endogenous convulsants [1]. It has been proposed that
most GCs are synthesized via transamidination of the
amidino group from arginine to amino acids and neuro-
transmitters [1] (Figure 1). CT biosynthesis involves two
sequential steps catalyzed by L-arginine:glycine amidino-
transferase (AGAT) and S-adenosylmethionine:guanidi-
noacetate N-methyltransferase (GAMT), producing the
CT biosynthetic precursor GAA and CT, respectively.
CTN is non-enzymatically produced from CT.
The brain barriers might be key determinants of the
levels of GCs in the brain and cerebrospinal fluid (CSF).
The brain barriers consist of the blood-brain barrier
(BBB) and the blood-cerebrospinal fluid barrier (BCSFB).
T h eB B Ba n dB C S F Ba r ef o r m e db yt i g h tj u n c t i o n so f
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epithelial cells, respectively, and serve to regulate the
supply of essential nutrients into the brain/CSF and the
elimination of xenobiotics and endogenous metabolites
from the brain/CSF via various transport systems such as
transporters [5,6]. It is thus conceivable that transporters
for GCs play an essential role in the influx and efflux
transport of GCs at the BBB and/or the BCSFB. However,
evidence on the molecular mechanism(s) of GCs trans-
port between the circulating blood and the brain
Figure 1 Putative synthetic pathways of guanidino compounds in the brain.
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the brain barrier transport and cerebral distribution of
GCs. In this review, we present an overview of the BBB
and the BCSFB transport of GCs and related amino acids
and neurotransmitters.
Relevance of GCs transport at the brain barriers
to neural disorders
A physiological importance of CT in the brain has been
evidenced in inherited CT deficiency syndrome (CDS),
which is characterized by the absence or severe reduc-
tion of CT in the brain [7]. Patients exhibit mental
retardation, delayed speech and language delay, epilepsy,
extrapyramidal signs, and autistic behavior [8]. CDS is
associated with genetic defects in AGAT [9,10], GAMT
[11], and CT transporter (CRT/solute carrier (SLC)
6A8) [12]. It has been believed that the blood-to-brain
CT supply is limited by the BBB, and that cerebral CT
is largely derived from biosynthesis in the brain. Indeed,
CT has a net positive charge and an estimated log parti-
tion coefficient of -2.7 [13], which would not be consis-
tent with diffusion of CT through plasma membranes.
Furthermore, oral administration of 20 g CT per day for
4 weeks produced only a 9% increase in total CT in
human brain [14]. On the other hand, in patients with
AGAT and GAMT deficiency, oral CT administration
increased the CT level in the brain [11] and improved
the neurologic symptoms [9,15]. However, patients with
CRT deficiency do not show improvement of neurologi-
cal symptoms following oral CT supplementation
[16-18], despite the presence of CT biosynthetic
enzymes and normal levels of plasma CT. These lines of
evidence prompted us to hypothesize that CRT is
e x p r e s s e da tt h eB B Ba n dm e d i a t e st h et r a n s p o r to fC T
from the circulating blood to the brain. To test this
idea, it is necessary to identify the origin of CT in the
brain.
Cerebral accumulation of GAA contributes to neuro-
logical complications, such as epilepsy and seizures, in
patients deficient in GAMT [8]. It has been postulated
that GCs cannot undergo active brain-to-blood efflux
across the brain barriers, so that cerebral accumulation
of GCs may occur. This is consistent with the concept
that one of the functions of the BBB is to retain neuro-
transmitters and nutrients in the brain. Consequently,
increased levels of GCs in the brain may be associated
with epileptic discharges and convulsions. GAA is com-
monly found to be elevated in brains having an epilepto-
genic focus and in CSF of several animal models of
epilepsy [1]. In contrast, it has been reported that endo-
genous levels of GAA in CSF increased at the onset of
convulsions but returned to the basal level after the con-
vulsions had ceased [19], supporting the idea that the
brain possesses a clearance system for GCs via the brain
barriers. It has recently been established that the brain
barriers act as a clearance system for various metabolites
and neurotoxic compounds produced in the brain [6].
Clarifying the cerebral clearance system of GCs from
the brain and CSF should therefore provide insight into
how abnormal accumulation of GCs in the brain and
CSF can be prevented.
Methodology for evaluation of BBB and BCSFB
transport
The in vivo blood-to-brain and blood-to-CSF influx
transports across the BBB and BCSFB have been evalu-
ated by means of integration plot analysis and the brain
uptake index (BUI) method after intravenous and caro-
tid artery injection of radiolabeled compounds, respec-
tively [20-22]. This method enables us to calculate the
apparent brain/CSF uptake clearance (CLinflux, BBB,C L in-
flux, BCSFB). The in vivo brain-to-blood efflux transport
clearance (CLefflux, BBB) across the BBB has been deter-
mined by means of the brain efflux index (BEI) method
[23]. After microinjection of a mixture of radiolabeled
test and reference compounds into the cerebrum, the
remaining amounts of test and reference compounds in
the ipsilateral cerebrum are measured. The reference
compound, which does not cross the BBB, is used to
determine the amount of test compound injected.
Apparent efflux clearance reflects the efflux transport
process across the BBB, but not across the BCSFB. The
in vivo efflux clearance from CSF has been evaluated by
means of the intracerebroventricular administration
method [24]. After intracerebroventricular administra-
tion of a test compound, the remaining amount of test
compound in the CSF is determined. The molecular
mechanisms responsible for BBB and BCSFB transport
have been investigated by using our established condi-
tionally immortalized rat/mouse brain endothelial cell
line (TR/TM-BBB) [25,26], rat choroid plexus epithelial
cell line (TR-CSFB) [27] and freshly isolated choroid
plexus. TR/TM-BBB cells and TR-CSFB cells retain the
in vivo expressions and functions of several transporters
and are a suitable in vitro model for the BBB [28] and
BCSFB [5], respectively. A number of transporters
expressed at the BBB and BCSFB have been identified as
playing roles in nutrient supply and drug distribution to
t h eb r a i na n dt h eC S Fb yu s i n gT R / T M - B B Bc e l l sa n d
TR-CSFB cells [6].
Transport of GCs precursor amino acids and
neurotransmitters across the BBB
The BBB possesses influx and efflux transport systems
for GCs precursor amino acids and neurotransmitters,
as illustrated in Figure 2. L-Arginine is transported from
the circulating blood into the brain via Na
+-independent
cationic amino acid transporter 1 (CAT1/SLC7A1)
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transport at the rat BBB is saturable with a Michaelis-
Menten constant (Km) value of 56 μM, which is lower
than the physiological serum concentration of L-arginine
in rat (170 μM [31]) and in human (100 μM [32]). Since
L-arginine in mammals is derived mostly from renal de
novo synthesis and dietary intake, CAT1 at the BBB
would function as a supply pathway for L-arginine to
the brain. The blood-to-brain transport of glycine across
the BBB appears to be a passive diffusion, since [
14C]gly-
cine uptake by the brain was not inhibited by unlabeled
glycine [20]. Zlokovic et al. [33] found, using the BUI
method, that the BUI value of glycine was close to that
of sucrose, used as a BBB impermeable paracellular
marker. Since L-serine is possibly converted to glycine
in the brain [34,35], glycine in the brain would be sup-
plied by de novo synthesis, rather than via glycine influx
transport at the BBB.
L-Glutamic acid, L-aspartic acid, glycine, g-aminobuty-
ric acid (GABA), and taurine undergo efflux from the
brain into the circulating blood across the BBB [36-39].
A physiological role for the efflux transport processes at
the BBB would be to remove the neurotransmitters and
amino acids from the brain interstitial fluid and to
maintain these extracellular concentrations below neu-
rotoxic levels [40] if they had overflowed from neurons
and glial cells under conditions of cerebral dysfunction,
such as brain ischemia.
The brain-to-blood efflux transport across the BBB
consists of two steps, i.e., influx across the abluminal
membrane from the brain interstitial fluid into brain
capillary endothelial cells and subsequent efflux across
the luminal membrane from endothelial cells into the
circulating blood. Na
+-dependent transporters, such as
EAAT (excitatory amino acid transporter) 1/SLC1A3,
EAAT2/SLC1A2, and EAAT3/SLC1A1, for glutamate
exist on the abluminal membranes of brain capillary
endothelial cells [41]. These transporters mediate gluta-
mate transport from the brain interstitial fluid into
endothelial cells. When the glutamate concentration in
endothelial cells becomes greater than that in the
plasma, glutamate would be effluxed from the endothe-
lial cells into the circulating blood in a facilitative man-
ner [42,43]. Alanine-serine-cysteine transporter 2
(ASCT2/SLC1A5), mediates L-isomer-selective uptake
of aspartic acid on the abluminal membrane of brain
capillary endothelial cells in an Na
+- and pH-dependent
manner [44]. Na
+-dependent amino acid transporter A2
(ATA2/SLC38A2) is predominantly expressed at the
abluminal membrane of the brain capillary endothelial
cells at the BBB and transports system A substrates,
such as glycine and L-proline [39]. Mouse Na
+-depen-
dent GABA transporter 2/betaine-GABA transporter 1
(GAT2/BGT1/SLC6A12) is expressed in brain capillary
endothelial cells and is involved in GABA efflux trans-
port across the BBB [45]. Taurine efflux transport across
the BBB is a saturable process with a Km of 39.1 μM
[38]. This Km value is similar to that of rat taurine
transporter (TauT/SLC6A6) [46], suggesting that TauT
is involved in taurine efflux transport across the BBB.
In contrast to L-glutamic acid, L-aspartic acid, glycine,
GABA, and taurine, not only is D-aspartic acid retained
in the brain parenchymal cells, but also there is no
efflux transport system for D-aspartic acid at the BBB
[36]. This would facilitate the accumulation of D-aspar-
tic acid in the brain. While the BBB acts as an efflux
pump for L-aspartic acid and L-glutamic acid to reduce
the brain interstitial concentration, it acts as a static
wall for D-aspartic acid.
Characteristics of transporters for GCs
Several transporters which belong to the SLC6 gene
family are likely to accept GCs as substrates (Table 1).
T h eS L C 6m e m b e r sa r eN a
+-a n dC l
--dependent trans-
porters for neurotransmitters, amino acids and osmo-
lytes, including GABA, betaine, taurine, and CT [47].
CRT mediates transport of CT, GAA, and CTN, with Km
values of 46 μM/29 μM [48,49], 269 μM/412 μM [50],
and 52 mM [51], respectively. The transport affinities of
GAA and CTN for CRT are one and three orders of mag-
nitude lower than that of CT, respectively. CT competi-
tively inhibits CRT-mediated GAA transport with a Ki
value of 60.5 μM [50]. Therefore, it is necessary to con-
sider the physiological fluid concentrations of CT and
GAA in order to evaluate the actual contribution of CRT
to GAA transport. Since CRT is an electrogenic transpor-
ter, CT induces an inward current in Xenopus oocytes
expressing human CRT at a holding potential of -60 mV
Figure 2 Transport characteristics of guanidino compounds
precursor amino acids and neurotransmitters at the BBB.
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induces significant inward current in CRT-expressing,
but not water-injected, oocytes [50]. In the inhibition
study, CRT-mediated GAA transport was significantly
inhibited by GES, but not by taurine or GABA [50]. PCT
and CTN induce inward current to a lesser extent in
CRT-expressing oocytes, while GSA and MG do not
induce inward current [50]. Thus, GPA, GBA and GES
are potent substrates for CRT, whereas CRT does not
r e c o g n i z eG S A ,M G ,t a u r i n eo rG A B Aa sas u b s t r a t e .
Dodd and Christie [53] have reported that two or three
amino acid substitutions result in the loss of CT trans-
porter activity and gain of a specific GABA transporter
function. Because GPA inhibits mouse GABA transporter
3 and 4 (GAT3/SLC6A13 and GAT4/SLC6A11) [54,55],
there is a possibility that mouse GAT3 and GAT4 med-
iate transport of GCs. Therefore, these amino acid resi-
dues may be involved in GAT-mediated transport of GCs
which are not CRT substrates. TauT accepts taurine,
GAA, and GABA as substrates with Km values of 43 μM
[46], 215 μM [56] and 1.46 mM [57], respectively. The
transport affinities of GAA and GABA for TauT are
approximately one and two orders of magnitude lower
than that of taurine, respectively. TauT-mediated GAA
uptake is significantly inhibited by taurine, GABA, GPA,
GBA and GES, whereas CT, GSA, MG and CTN have no
effect [56]. This result suggests that GPA, GBA and GES
are good substrates for TauT, whereas CT, GSA, MG,
and CTN are not.
Rat organic cation transporter 3 (rOCT3/SLC22A3)
and human OCT2 (hOCT2/SLC22A2) mediate low-affi-
nity CTN transport with Km values of 47.7 mM [51]
and 4.0 mM [58], respectively. In contrast, human
OCT1 (hOCT1/SLC22A1) does not recognize CTN
[58]. MG inhibits rOCT3-mediated CTN transport [51],
implying that MG is also a substrate for rOCT3. Guani-
dine, GSA and MG inhibit hOCT1 and/or hOCT2-
mediated tetraethylammonium uptake, while GAA has
little effect on the uptake [59]. Thus, the SLC22 mem-
bers are likely to mediate transport of GSA, CTN, gua-
nidine, and MG, which are not recognized by the SLC6
family members.
Transport of CT across the BBB
In human brain, the CT concentration (7.4 mM) is
approximately 190-fold greater than that in the plasma
Table 1 Inhibitory effect of various compounds on [
14C]GAA uptake by HEK293 cells stably overexpressing CRT (CRT/
HEK293 cells) and Xenopus oocytes expressing CRT (CRT/oocytes) or TauT (TauT/oocytes), and [
14C]CTN uptake by
Xenopus oocytes expressing rOCT3(rOCT3/oocytes)
Inhibitor [
14C]GAA uptake [
14C]CTN uptake
CRT/HEK293 cells
%of control
CRT/oocytes
%of control
TauT/oocytes
%of control
rOCT3/oocytes
%of control
Control 100 ± 4 100 ± 9 100 ± 9 100 ± 19
Guanidinoacetate (GAA) 19.2 ± 2.6* 44.6 ± 2.7* 53.2 ± 9.6* -
b-Guanidinopropionate (GPA) 1.81 ± 0.14* 0.944 ± 0.189* 4.77 ± 0.66* 143 ± 21
g-Guanidinobutyrate (GBA) 10.0 ± 0.6* 21.4 ± 2.0* 21.7 ± 4.2* -
Guanidinoethansulfonate (GES) 23.1 ± 1.1* - 4.66 ± 0.22* -
Guanidinosuccinate (GSA) 101 ± 1 107 ± 12 103 ± 10 -
Creatine (CT) 3.06 ± 0.24* 2.91 ± 0.23* 98.4 ± 12.7 137 ± 24
Taurine 111 ± 5 - 3.00 ± 0.19* -
g-Aminobutyric acid (GABA) 95.5 ± 2.9 - 34.0 ± 4.6* -
Creatinine (CTN) 93.3 ± 5.3 123 ± 10 97.9 ± 14.6 -
Methylguanidine (MG) 82.3 ± 15.2 126 ± 14 110 ± 18 47.2 ± 18.9**
Creatine phosphate (PCT) 93.4 ± 6.8 97.9 ± 14.1 117 ± 6 -
Guanidine 114 ± 6 88.2 ± 13.4 - 137 ± 22
L-Arginine 86.6 ± 6.3 - - -
Glycine 126 ± 4 - - -
L-Alanine 111 ± 3 - - -
L-Aspartic acid 98.5 ± 2.2 - - -
Tetraethylammonium 128 ± 29 82.8 ± 7.3 - 48.1 ± 8.3**
Benzylpenicillin 110 ± 14 115 ± 12 - -
[
14C]GAA (20-45 μM) and [
14C]CTN (70 μM) uptake by CRT/oocytes, TauT/oocytes and rOCT3/oocytes was measured at 20°C for 60 min in the absence (control) or
presence of inhibitors (2 mM). [
14C]GAA (3 μM) uptake by CRT/HEK293 cells was measured at 37°C for 5 min in the absence (control) or presence of inhibitors (2
mM). Each value represents the mean ± SEM (n = 4-8 for CRT/HEK293 cells, n = 10-25 for CRT/oocytes, TauT/oocytes and rOCT3/oocytes). *p < 0.01, **p < 0.05,
significantly different from control. -, not determined.
Modified and reproduced from Tachikawa et al. [50,51,56].
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transported from the circulating blood to the brain via a
carrier-mediated transport system at the BBB [21]. The
[
14C]CT influx transport clearance across the BBB was
1.61 μL/(min￿g brain), which is about 6-fold greater
than that of [
14C]sucrose [60], a BBB impermeable
paracellular marker in rats. The apparent cerebrum-
to-plasma concentration ratio of [
14C]CT reaches
30.8 mL/g tissue 24 hours after exogenous administra-
tion of [
14C]CT to mice. This value is consistent with
the endogenous brain-to-serum concentration ratio of
CT [3], suggesting that the BBB functions as a major
pathway for supplying CT to the brain from the circu-
lating blood.
The characteristics of [
14C]CT uptake by TM-BBB
cells support the idea that CRT is involved in CT trans-
port at the BBB [21]. [
14C]CT uptake by TM-BBB cells
takes place in an Na
+-, Cl
-- and concentration-depen-
dent manner with a Km value of 16.2 μM, which is con-
sistent with the apparent Km values of 29 μMf o r
human CRT [61] and 15 μMf o rr a tC R T[ 4 8 ] .G P A
causes marked inhibition of [
14C]CT uptake by TM-BBB
cells as reported elsewhere [62]. The corresponding Km
value is 10- to 40-fold lower than the plasma concentra-
tion (140-600 μM) in mouse and rat [2]. The blood-to-
brain transport of CT is more than 90% saturated by
endogenous plasma CT, and CRT at the BBB plays a
role in continuously supplying CT from the circulating
blood to the brain at a constant rate equivalent to the
maximal velocity. This suggests that the efficacy of oral
CT treatment for patients with neurodegenerative dis-
eases may depend on the CRT function at the BBB.
Belanger et al. [63] have found that the mRNA expres-
sion and function of CRT in TM-BBB cells are increased
under hyperammonemic conditions. CRT function at
the BBB might be highly regulated under pathophysiolo-
gical conditions.
Immunohistochemical studies have indicated that CRT
is localized at both the luminal and abluminal sides of
mouse brain capillary endothelial cells in the adult brain
[21,64]. CRT is also expressed in neurons [21,65], sug-
gesting that CT is transported into neurons by CRT fol-
lowing BBB transport. In support of this notion, in vitro
studies reveal that an exogenous supply of CT increases
the neuronal PCT store and protects neurons from
hypoxic damage, glutamate excitotoxicity and b-amy-
loid-induced toxicity [66,67]. Oral administration of CT
has been reported to protect neurons in animal models
of amyotrophic lateral sclerosis, Huntington’sd i s e a s e
and Parkinson’s disease [68-70]. Thus, the processes of
CT transport at the BBB are important for understand-
ing the mechanism governing the supply of CT to the
brain and information about them could help in the
design of improved oral CT supplementation for the
treatment of neurodegenerative diseases and CDS.
Transport of GAA across the BBB and BCSFB
GAA is present at low concentrations (2-12 μM) in nor-
mal mammalian brain [3]. In contrast, the GAA level in
the brain of GAMT-knockout mice (1.85-1.87 mM) is
approximately 150-fold greater than that in normal
brain (12 μM) [71,72]. Since GAA exerts an epilepto-
genic effect by affecting GABAergic neurotransmission
[73], an increased level of GAA in the brain appears to
affect brain function. We have investigated why GAA is
abnormally accumulated in the brains of patients with
GAMT deficiency.
Brain-to-blood efflux transport of GAA across the BBB
and BCSB
In vivo and ex vivo studies reveal that there is no efflux
transport of GAA across the BBB, and instead GAA
undergoes efflux transport from the CSF [50,56]. [
14C]
GAA microinjected into rat cerebrum was not effluxed
from the brain across the BBB [56], whereas the elimi-
nation clearance of GAA via the BCSFB (3.97 μL/min
per rat) [50] is still approximately 33-fold greater than
the apparent blood-to-CSF influx clearance of GAA
(0.122 μL/min per rat) [56]. This predominant GAA
efflux transport at the BCSFB can explain the fact that
the GAA concentration in human CSF (0.036-0.22 μM)
is almost one order of magnitude lower than that in
plasma (0.35-3.5 μM) [8]. This also may help to explain
the rapid removal of increased GAA from the CSF at
the onset of convulsions [19], preventing the continua-
tion of convulsions and seizures.
GAA transport at the BCSFB is mediated at least par-
tially by CRT and TauT, which may make approximately
50% and 11% contributions to total GAA uptake by the
choroid plexus, respectively [50,56]. The functional
expression of CRT at the BCSFB is supported by the
brush-border membrane localization of CRT in choroid
plexus epithelial cells and the observation of Na
+-a n d
Cl
--dependent [
14C]CT uptake by TR-CSFB [50]. TauT
appears to be expressed on the brush-border membrane
of choroid plexus epithelial cells [74]. The Km value of
Na
+-dependent GAA uptake by TR-CSFB cells (929
μM) is comparable with that of GAA uptake by CRT-
expressing HEK293 cells (412 μM)/Xenopus laevis
oocytes (269 μM), as well as that of TauT-expressing
Xenopus laevis oocytes (215 μM) [50,56]. The in vivo
process of GAA elimination from the CSF was partially
inhibited by CT and taurine [50,56].
Interestingly, one clinical report has demonstrated that
patients with CRT deficiency exhibit increased GAA
levels, as well as the absence of CT in the brain [75],
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CRT and the increase in brain GAA level. Although neu-
rological complications in patients with CRT deficiency
would be caused mainly by the lack of CT transport in
neuronal cells, the dysfunction of CRT may also lead to
an increase in GAA in the brain, owing to the lack of
CRT-mediated GAA efflux transport across the BCSFB.
In patients with GAMT deficiency, GAA is accumulated
in the CSF (11-15 μM), whereas CT levels in the CSF are
significantly decreased (< 2.0 μM). However, GAA con-
centration in the CSF of these patients is still lower than
that in the brain parenchyma [76] or plasma [8]. This is
because CRT and TauT would play an important role in
the efflux transport of GAA from the CSF at the BCSFB.
Indeed, the Km value of GAA uptake by TR-CSFB cells
(926 μM) [50] is greater than the GAA concentration in
the CSF of the patients (11-15 μM [76]).
Blood-to-brain influx transport of GAA across the BBB
GAA influx transport via CRT at the BBB would also play
a key role in the cerebral accumulation of GAA in
patients with GAMT deficiency. The characteristics of
Na
+-a n dC l
--dependent [
14C ] G A Au p t a k eb yT R - B B B
cells are consistent with those of CRT, but not TauT
[50]. The Km value of 556 μM in TR-BBB cells is com-
parable with that obtained for GAA uptake using CRT-
expressing Xenopus laevis oocytes (269 μM)/HEK293
cells (412 μM). Taurine has no significant effect on the
GAA uptake. CRT is localized in mouse brain capillary
endothelial cells and mediates CT influx transport across
the BBB [21,64]. Considering that the Km value of rat
CRT-mediated CT transport is 46 μM/29 μM [48,49], the
function of CRT on the luminal membrane could be 85-
90% saturated by endogenous CT in the serum under
physiological conditions (250 μM in rats [3]). Thus, it
appears that CRT-mediated transport of GAA at the BBB
is almost wholly inhibited by CT in the blood under nor-
mal conditions. In patients with GAMT deficiency, the
CT levels in the plasma (1-5 μM) are smaller than refer-
ence values (6-109 μM), whereas the GAA levels in the
plasma (12-39 μM) are greater than reference values
(0.35-3.5 μM) [8]. Although the influx and efflux trans-
port of GAA across the brain barriers are well balanced,
at least under normal conditions [56], the degree of CRT
saturation by endogenous CT in the circulating blood of
the patients would be smaller, thus contributing to the
significant increase of the blood-to-brain GAA transport.
This mechanism could explain the fact that treatment
with CT supplementation resulted in partial normaliza-
tion of cerebral levels of CT and GAA in patients [77].
GAA transport in brain parenchymal cells
[
14C]GAA is taken up by brain parenchymal cells in a
concentrative manner, presumably via CRT, TauT and
other Na
+-dependent carrier-mediated system(s) [56].
This would be another reason for the accumulation of
GAA in the brain of patient with GAMT deficiency.
The contribution of CRT to the GAA uptake by brain
parenchymal cells appears to be small, because CT does
not inhibit the GAA uptake by more than 11% even at
a concentration of 10 mM. It has been reported that
there is a relationship between gene polymorphism of
CRT, transport activity of CRT, and neurological symp-
toms such as developmental delay, mental disorder and
epilepsy with seizures [78-80]. Almeida et al. [81] pro-
posed that exocytotic release of CT into the brain inter-
stitial fluid acts as a neuromodulator of GABAergic
neurotransmission. Thus, CRT may be mainly responsi-
b l ef o rt h eu p t a k eo fC Tb yC R T - e x p r e s s i n gn e u r o n s
and oligodendrocytes to maintain the proper GABAer-
gic neurotransmission. GPA inhibits the GAA uptake by
brain slices by 89%, which is greater than the inhibitory
effect of taurine plus CT (59%), but similar to the effect
of Na
+-depletion (92%) [56]. Since GPA is a potent
inhibitor of mouse GAT3 and GAT4 [54,55], as well as
of CRT- and TauT-mediated GAA uptake (Table 1),
there is a possibility that the GATs play a role in GAA
uptake.
In summary, the key factors facilitating GAA accumu-
lation in the brains of patients with GAMT deficiency
could be (i) the lack of efflux transport across the BBB,
(ii) the increase of CRT-mediated blood-to-brain GAA
transport at the BBB, and (iii) the Na
+-dependent con-
centrative GAA transport by brain parenchymal cells.
Transport of CTN across the BBB and BCSFB
S e v e r a lG C s ,s u c ha sC T N ,M G ,g u a n i d i n e ,a n dG S A ,
are involved in the typical manifestations, such as epi-
leptic and cognitive symptoms, of uremic encephalopa-
thy [82]. Levels of uremic GCs are substantially
increased in serum, CSF, and brain of nondialyzed
patients with renal insufficiency [83,84]. The highest
CTN concentration in the CSF of severely uremic
patients is 521 μM, which is about 8-fold greater than
that in control subjects (67.6 μM) [82]. The uremic GC
concentrations observed in the brain of uremic patients
are similar to those producing convulsive effects [82],
and so could contribute to the neurological complica-
tions suffered by these patients [85]. Since no specific
saturable uptake mechanism exists for CTN in human
red blood cells [86], it has been postulated that CTN
diffuses out of the brain. In the kidney, CTN is excreted
into urine by tubular secretion, as well as glomerular fil-
tration. Human OCT2, but not hOCT1, mediates the
tubular secretion of CTN at the basolateral membrane
of renal proximal tubular cells [58]. These findings pose
a question as to whether CTN undergoes efflux from
the brain only by diffusion.
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Emerging evidence indicates that the BCSFB is the
major pathway of cerebral CTN clearance, and transpor-
ter-mediated processes, at least in part via rOCT3, are
involved in CTN efflux transport from the CSF at the
BCSFB [51]. CTN, after intracerebral administration, is
not significantly eliminated from the brain across the
BBB, whereas the elimination clearance of CTN from
the CSF is 60-fold greater than that of inulin (reflecting
CSF bulk flow). Even in renal failure model rats, the
ratio of increase of the CTN concentration in CSF was
smaller than that in plasma, suggesting a significant role
for the CSF-to-blood efflux process. The inhibitory
effects of inhibitors and antisense oligonucleotides on
[
14C]CTN uptake by isolated choroid plexus indicate the
involvement of rOCT3 and CRT in CTN transport. Rat
OCT3 is functionally expressed in choroid plexus
epithelial cells [87]. Since endogenous compounds in
the CSF may affect rOCT3- and CRT-mediated trans-
port of CTN in the choroid plexus, the physiological
conditions in the CSF should be taken into account in
evaluating the actual contributions of rOCT3 and CRT.
Considering the Km value of CRT for CT (46 μM/29
μM [48,49]) and the normal CSF concentration of CT
(24-66 μM [8]), CRT on the brush-border membrane of
the choroid plexus epithelial cells may be approximately
50% saturated by endogenous CT in the CSF. Further-
more, the Km value of CRT for CTN (52 mM) [51] is
almost 3 orders of magnitude greater than the Km value
of CRT for CT. Thus, it is unlikely that CRT plays a
role in the elimination of CTN from the CSF. Therefore,
it appears that CTN efflux transport, at least in part via
rOCT3, at the BCSFB plays a crucial role in the efficient
removal of CTN from the CSF. Indeed, the Km value of
rOCT3-mediated CTN transport (47.7 mM) [51] is still
much higher than the CTN concentration in the CSF of
patients with renal failure (168-521 μM [85]), suggesting
that rOCT3 functions as a CTN transporter without
saturation.
Blood-to-brain influx transport of CTN across the BBB
The blood-to-brain influx clearance of CTN is approxi-
mately 14-fold greater than that of sucrose, used as a
BBB impermeable paracellular marker [60]. This evi-
dence implies that the blood-to-brain transport of CTN
is carrier-mediated, rather than occurring simply by pas-
sive diffusion. In this regard, elevated levels of CTN in
the brain of the patients with renal insufficiency might
be due to increased permeability of CTN in the blood-
to-brain direction. Therefore, it will be clinically benefi-
cial, as far as the cerebral accumulation of CTN is con-
cerned, to block the BBB influx transport of CTN in
patients with renal insufficiency.
Conclusion
Our recent research provides a novel insight into how
physiologically important and/or neurotoxic GCs are
accumulated in the brain under physiological and patho-
logical conditions. Transporters for GCs at the BBB and
BCSFB have emerged as determinants of GCs distribu-
tion to the brain as summarized in Figure 3. CRT
expressed at the BBB regulates the CT concentration in
the brain at millimolar levels as a major pathway for
supplying CT from the circulating blood to the brain.
CRT may also be a key factor in blood-to-brain GAA
transport in patients with GAMT deficiency, causing
abnormal accumulation of GAA in the brain. CRT,
T a u Ta n dO C T 3e x p r e s s e da tt h eB C S F Ba r ei n v o l v e d
in GAA and/or CTN efflux transport from the CSF.
Interestingly, BBB efflux transport of GCs, including
GAA and CTN, is negligible, though the BBB has a vari-
ety of efflux transport systems for synthetic precursors
of GCs, such as amino acids and neurotransmitters.
Instead, the BCSFB functions as a major cerebral clear-
ance system for GCs. These findings should help us
identify the molecular mechanism(s) of neurological
complications in unexplained convulsions and seizures.
The regulatory mechanisms of GCs transport at the
BBB and BCSFB need to be further clarified to provide
a more rational basis for therapy of neuronal disorders
caused by accumulation of GCs and insufficiency of CT
in the brain. Such information should also aid the dis-
covery and development of drugs which facilitate efflux
transport of GCs at the BBB and the BCSFB in order to
prevent accumulation of GCs, as well as drugs which
facilitate the influx transport of CT at the BBB to pro-
mote efficient supplementation of CT.
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